

# ALLERGIC SPECIALTY MEDICATIONS FORM

## PATIENT INFORMATION

Last Name \_\_\_\_\_ First Name \_\_\_\_\_  
 Social Security No \_\_\_\_\_ Date of Birth \_\_\_\_\_  
 Sex  M  F Weight \_\_\_\_\_ Height \_\_\_\_\_ Allergies \_\_\_\_\_  
 Home Phone \_\_\_\_\_ Work/Mobile \_\_\_\_\_  
 Home Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

## PATIENT INSURANCE INFORMATION

Primary Medical Insurance \_\_\_\_\_ Medical Insurance Phone \_\_\_\_\_  
 Subscriber Name \_\_\_\_\_  
 Rx Card (PBM) \_\_\_\_\_ Group No \_\_\_\_\_  
 Prescription Card Bin # \_\_\_\_\_ PCN # \_\_\_\_\_

## TREATMENT ARRANGEMENTS

• Start Date: \_\_\_\_\_ Ship Meds  Home  Doctor's Office  
 Teaching by:  Doctor's Office  Other: \_\_\_\_\_

### CERTIFICATE OF MEDICAL NECESSITY

Diagnosis (ICD-10):  J45.40 Moderate persistent asthma uncomplicated  J45.50 Severe persistent asthma uncomplicated  L20.9 Atopic dermatitis

Serum total immunoglobulin E (IgE) level (IU/mL) \_\_\_\_\_ Body Weight: \_\_\_\_\_

Other: \_\_\_\_\_

## PRESCRIPTION INFORMATION

DRUG	STRENGTH	DIRECTION	QUANTITY	REFILLS
<input type="checkbox"/> <b>DUPIXENT®</b> (dupilumab)	<input type="checkbox"/> 300mg/2ml Prefilled Syringe	<input type="checkbox"/> Inject 600mg (2 Prefilled Syringe) Subq in different sites on day 1. <input type="checkbox"/> Inject 300mg (1 Prefilled Syringe) Subq every other week starting day 15 after initial dose. <input type="checkbox"/> Others: _____		
<input type="checkbox"/> <b>XOLAIR®</b> (omalizumab) <input type="checkbox"/> Vial <input type="checkbox"/> Prefilled Syringe	<input type="checkbox"/> 75mg <input type="checkbox"/> 150mg <input type="checkbox"/> 225mg <input type="checkbox"/> 300mg <input type="checkbox"/> 375mg	<input type="checkbox"/> Inject _____ mg/dose Subq every 2 weeks. <input type="checkbox"/> Inject _____ mg/dose Subq every 4 weeks. <input type="checkbox"/> Others: _____		
<input type="checkbox"/> <b>NUCALA®</b> (mepolizumab)	<input type="checkbox"/> 100mg	<input type="checkbox"/> Inject 100mg Subq once every 4 weeks. <input type="checkbox"/> Others: _____		
<input type="checkbox"/> <b>CINQAIR®</b> (reslizumab)	<input type="checkbox"/> _____ mg/kg	<input type="checkbox"/> Inject _____ mg/kg once every 4 weeks by intravenous infusion over 20-50 minutes. <input type="checkbox"/> Others: _____		
<input type="checkbox"/> <b>FASENRA®</b> (benralizumab)	<input type="checkbox"/> 30mg	<input type="checkbox"/> Inject 30mg Subq every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter. <input type="checkbox"/> Others: _____		
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		

Skilled nursing visit for self injection training and one additional visit with next dose if needed.

Physician Signature **X**: \_\_\_\_\_  DAW (Dispense as Written) Date: \_\_\_\_\_

Physician Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Office Contact: \_\_\_\_\_

Physician Address: \_\_\_\_\_ NPI: \_\_\_\_\_ DEA: \_\_\_\_\_

**IMPORTANT NOTICE:** This message may contain privileged and confidential information and is intended only for the individual only for the individual named. If you are not the named addresses, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake. Then destroy this document. Please direct all verification or notification to the above mentioned physician's office.

By Signing this prescription and using Southside pharmacy's services you authorize Southside Pharmacy to contact Insurance companies for prior authorization purposes on your behalf.